Low TFAP2A expression BRCA patients were predicted to obtain better immunotherapy efficacy in receiving CTLA4 or PD-1 blockade treatment, but related to unsatisfying immunotherapy efficacy in COAD patients. Here, TFAP2A is linked to colon adenocarcinoma.